http://rdf.ncbi.nlm.nih.gov/pubchem/patent/KR-102081810-B1
Outgoing Links
| Predicate | Object |
|---|---|
| classificationCPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1271 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-1277 http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-186 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K45-06 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-127 |
| filingDate | 2017-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationDate | 2020-05-28-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | KR-102081810-B1 |
| titleOfInvention | Liposome encapsulated with double anti-cancer drug and method for producing the same |
| abstract | The present invention relates to a liposome encapsulated with an anticancer agent and a method for manufacturing the same, and instead of a citric acid buffer used in a conventionally known method when preparing a liposome encapsulated with a hydrophobic anticancer agent and a hydrophilic anticancer agent, contains ammonium sulfate. When the solution is used and the hydrophobic anti-cancer drug to lipid ratio is decreased, the encapsulation efficiency of the hydrophobic anti-cancer agent as well as the hydrophilic anti-cancer agent is relatively high. |
| priorityDate | 2017-12-26-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 86.